Soleno Therapeutics, Inc. (SLNO)
After hours:
| Previous close | 0.4201 |
| Open | 0.4202 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 3100 |
| Day's range | 0.4050 - 0.4381 |
| 52-week range | 0.4010 - 3.3600 |
| Volume | |
| Avg. volume | 257,421 |
| Market cap | 33.056M |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3880 |
| Earnings date | 01 Mar 2022 - 07 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
- GlobeNewswire
Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event
REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel discussion during the LifeSci Partners 11th Annual Corporate Access Event. Details for the panel discussions are below: Title:Patient Advocacy: Honing the Skill for Crossover Communicat
- Zacks
Down 13.9% in 4 Weeks, Here's Why Soleno Therapeutics, Inc. (SLNO) Looks Ripe for a Turnaround
Soleno Therapeutics, Inc. (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- GlobeNewswire
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare disease, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to a new employee. The independent members of the Board of Directors of Soleno approved the grant of a non-qualified stock option to purchase 75,000 shares of common stock to Michael Woloschak, S
